Search results for "rolle"

showing 10 items of 3002 documents

Effects of exercise frequency and training volume on bone changes following a multi-component exercise intervention in middle aged and older men: Sec…

2021

Progressive resistance training (PRT) combined with weight-bearing impact exercise are recommended to optimize bone health, but the optimal frequency and dose of training remains uncertain. This study, which is a secondary analysis of an 18-month intervention in men aged 50–79 years, examined the association between exercise frequency and the volume of training with changes in DXA and QCT-derived femoral neck (FN) and lumbar spine (LS) bone outcomes, respectively. Men were allocated to either thrice-weekly PRT plus impact exercise training (n = 87) or a non-exercising (n = 85) group. Average weekly exercise frequency (ExFreq) and training volume per session [PRT volume (weight lifted, kg), …

0301 basic medicineMalemedicine.medical_specialtyHistologyweight-bearing exercisePhysiologyEndocrinology Diabetes and Metabolismluuntiheys030209 endocrinology & metabolismlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawBone DensitySecondary analysisMedicineHumansolder menExerciseFemoral neckAgeddose-responsekehonpainoharjoitteluLumbar VertebraeExercise interventionbusiness.industryFemur NeckResistance trainingResistance TrainingMiddle Agedkeski-ikäiset030104 developmental biologymedicine.anatomical_structurePhysical therapyLumbar spinemiehetvoimaharjoitteluresistance trainingbusinessbone mineral densityExercise frequencyikääntyneetVolume (compression)Bone
researchProduct

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-…

2019

Abstract Background Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions Our findings support in clinical practice …

0301 basic medicineMalemedicine.medical_specialtyMeta-AnalysiBone Density Conservation Agentmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsBone NeoplasmZoledronic Acidlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansHypocalcaemiaBreastAdverse effectBone Density Conservation AgentsSolid tumorbusiness.industryMortality rateProstateProstatic NeoplasmsAEHematologyBisphosphonateSMRmedicine.diseaseBone metastase030104 developmental biologyZoledronic acidTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisProstatic NeoplasmFemalebusinessBreast Neoplasmmedicine.drugHuman
researchProduct

Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms

2018

Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Dietary interventions based on protein restriction (PR) reduce circulating triglycerides (TGs), but underlying mechanisms and clinical relevance remain unclear. Here, we show that 1 week of a protein-free diet without enforced calorie restriction significantly lowered circulating TGs in both lean and diet-induced obese mice. Mechanistically, the TG-lowering effect of PR was due, in part, to changes in very low-density lipoprotein (VLDL) metabolism both in liver and peripheral tissues. In the periphery, PR stimulated VLDL-TG consumption by increasing VLDL-bound APOA5 expression and promoting VLDL-TG hydrolysis and…

0301 basic medicineMalemedicine.medical_specialtyVery low-density lipoproteinDietary proteinFGF21Calorie restrictionmTORC1Lipoproteins VLDLMechanistic Target of Rapamycin Complex 1Protein Serine-Threonine Kinases03 medical and health sciencesMice0302 clinical medicineRisk FactorsInternal medicinemedicineDiet Protein-RestrictedIntegrated stress responseAnimalsHumansCyclic AMP Response Element-Binding ProteinTriglyceridesRandomized Controlled Trials as TopicHypertriglyceridemiaChemistryHydrolysisHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseLipid Metabolism030104 developmental biologyEndocrinologyApolipoproteinsHypotriglyceridemiaLiverApolipoprotein A-Vlipids (amino acids peptides and proteins)Female030217 neurology & neurosurgeryLipoproteinResearch Article
researchProduct

Effect of chondroitin sulphate on synovitis of knee osteoarthritic patients.

2017

Abstract Objective To evaluate by ultrasonography the effect of chondroitin sulfate (CS) on synovitis in patients with knee osteoarthritis (KOA). To collaborate in the understanding of the biochemical mechanisms involved in the synovial inflammation process. Methods Randomized, single-blind, controlled trial involving 70 patients with primary KOA treated for 6 months with CS or acetaminophen (ACT). Evaluation of KOA status at baseline, 6 weeks, 3 and 6 months included: ultrasonography to assess synovitis (following the OMERACT expertise group definition), visual analogue scale and Lequesne index to measure pain and function, and ELISA to quantify inflammatory mediators in serum and synovial…

0301 basic medicineMalemedicine.medical_specialtyVisual analogue scaleInflammationPilot ProjectsOsteoarthritisGastroenterologylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineSynovitisMedicineSynovial fluidHumansSingle-Blind MethodChondroitin sulfateAcetaminophenAgedPain MeasurementUltrasonography030203 arthritis & rheumatologyAged 80 and overSynovitisbusiness.industryAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesMiddle AgedOsteoarthritis Kneemedicine.diseaseAcetaminophenBiomechanical Phenomena030104 developmental biologyTreatment OutcomechemistryFemalemedicine.symptombusinessBiomarkersmedicine.drugFollow-Up StudiesMedicina clinica
researchProduct

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.

1993

Since 1972, a large number of studies have shown that intravesical treatment with doxorubicin (adriamycin) is effective against carcinoma in situ and multiple papillary tumors. Furthermore, it significantly reduces the recurrence rate after transurethral resection. Its efficacy has been compared with that of Bacillus Calmette-Guerin (BCG), which is the only treatment accepted by the US Food and Drug Administration for therapy of carcinoma in situ (Tis). In more recent years, a few studies have been performed using intravesical epirubicin in the hope that different properties of the molecule might enhance the activity of the anthracyclines, but produce fewer and milder side-effects. After we…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyUrologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicineHumansPharmacology (medical)DoxorubicinEpirubicinPharmacologyChemotherapyUrinary bladderbusiness.industryCarcinoma in situCancermedicine.diseaseSurgeryInfectious Diseasesmedicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsDoxorubicin030220 oncology & carcinogenesisChemoprophylaxisbusinessCarcinoma in SituEpirubicinmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Can a Prebiotic Formulation Reduce Frailty Levels in Older People?

2019

Objective: The purpose of this study was to examine whether a prebiotic formulation reduces frailty index (FI) levels in older people. Design: We conducted secondary analysis of a placebo-controlled, randomized, double-blind design study. Setting/Participants: The study included non-demented people over the age of 65 who were living in nursing homes and were able to walk. Fifty participants completed the study (75.3±7.3 years, 70% females). Intervention: Participants were randomly assigned to either a group who received daily Darmocare Pre® (inulin and fructooligosaccharides) for 13 weeks or a placebo group (maltodextrin). Measurement: The primary outcome in this secondary analysis was chan…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentFrail ElderlyFrailty IndexOligosaccharidesPlacebo grouplaw.invention03 medical and health sciencesPrimary outcomeRandomized controlled trialDouble-Blind MethodlawSecondary analysismedicineHumansAgedAged 80 and overFrailtybusiness.industryPrebioticInulinGeneral Medicine030104 developmental biologyPrebioticsTreatment OutcomePhysical therapyFemalebusinessOlder peopleNursing homesThe Journal of frailtyaging
researchProduct

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

2019

Background Time in therapeutic range (TTR) measures the quality of vitamin K antagonist (VKA) anticoagulation. In patients with atrial fibrillation, the dichotomized SAMe-TT2-R2 score (≥2 vs. < 2 points) can predict if adequate TTR is unlikely to be achieved. Aims We validated the SAMe-TT2-R2 score in patients with venous thromboembolism (VTE) randomized to the warfarin arm of the Hokusai-VTE trial. Patients and Methods A total of 3,874 patients were included in the primary analysis (day 31–180 from randomization). The efficacy and safety outcomes were symptomatic recurrent VTE and major or clinically relevant non-major bleeding. Results The rates of recurrent VTE and bleeding events we…

0301 basic medicineMalevitamin K antagonistEXTERNAL VALIDATIONTime FactorsVitamin KWarfarin/therapeutic use030204 cardiovascular system & hematologyTHERAPYSeverity of Illness Indexlaw.inventionchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawRecurrenceAtrial FibrillationVitamin K/antagonists & inhibitorsStrokeRISKAtrial fibrillationHematologyVenous ThromboembolismVitamin K antagonistMiddle Agedrisk assessment modelTIMEPREDICTSTreatment OutcomeAnticoagulants/therapeutic useResearch DesignANTICOAGULATION CONTROLFemaleLife Sciences & Biomedicinemedicine.drugHemorrhage/drug therapyAdultmedicine.medical_specialtyRandomizationmedicine.drug_classvenous thromboembolismHemorrhageRisk AssessmentSensitivity and SpecificityEDOXABAN03 medical and health sciencesDouble-Blind MethodVITAMIN-K ANTAGONISTSInternal medicinemedicineNONVALVULAR ATRIAL-FIBRILLATIONORAL ANTICOAGULANTHumansInternational Normalized RatioBlood CoagulationScience & Technologybusiness.industryquality of treatmentWarfarinAnticoagulantsmedicine.diseasewarfarinClinical trial030104 developmental biologyPeripheral Vascular DiseasechemistryBlood Coagulation/drug effectsAtrial Fibrillation/bloodCardiovascular System & CardiologyLinear ModelsWarfarinbusinessVenous Thromboembolism/drug therapyThrombosis and haemostasis
researchProduct

Comprehensive evaluation of coding region point mutations in microsatellite-unstable colorectal cancer

2018

Microsatellite instability (MSI) leads to accumulation of an excessive number of mutations in the genome, mostly small insertions and deletions. MSI colorectal cancers (CRCs), however, also contain more point mutations than microsatellite-stable (MSS) tumors, yet they have not been as comprehensively studied. To identify candidate driver genes affected by point mutations in MSI CRC, we ranked genes based on mutation significance while correcting for replication timing and gene expression utilizing an algorithm, MutSigCV. Somatic point mutation data from the exome kit-targeted area from 24 exome-sequenced sporadic MSI CRCs and respective normals, and 12 whole-genome-sequenced sporadic MSI CR…

0301 basic medicineMedicine (General)Candidate geneclinical evaluationgenetic identificationgenetic analysisQH426-470medicine.disease_causeChromatin Epigenetics Genomics & Functional Genomicswhole exome sequencingddc:590mutator genesingle nucleotide polymorphismddc:576.5Gene Regulatory NetworksExomeExome sequencingCancercancer cellGeneticsMutation1184 Genetics developmental biology physiology3. Good healthgenetic codesyöpägeenitpriority journalMolecular Medicinewild typepoint mutationSystems MedicineColorectal Neoplasmscongenital hereditary and neonatal diseases and abnormalitiesddc:025.063/5703122 Cancerscancer geneticsSingle-nucleotide polymorphismcolorectal cancerBiologygene frequencyta3111mikrosatelliititcolony formationR105W geneArticle03 medical and health sciencesR5-920Gene interactionReportGeneticsmedicineHumanscontrolled studyhumanneoplasmspaksusuolisyöpäPoint mutationgene interactionhuman celltumor-related geneMicrosatellite instabilityMolecular Sequence AnnotationSequence Analysis DNAmedicine.diseaseta3122digestive system diseaseshuman tissueSTK38L gene030104 developmental biologyvalidation processgene expressionSMARCB1 genemicrosatellite instability3111 Biomedicinegene replicationReports
researchProduct

Mucoadhesive solid lipid microparticles for controlled release of a corticosteroid in the chronic obstructive pulmonary disease treatment.

2017

Therapeutic efficacy of inhaled drugs is limited by rapid clearance from the site of action due to absorption into systemic circulation or metabolic degradation by alveolar macrophages. Drug delivery systems offer new solutions to clinical problems especially in the treatment of pulmonary diseases. In particular, Solid Lipid Microparticles (SLM) in the range of 3-5 µm are suggested as systems for delivery of therapeutics to the lung as, because of their size, they are able to deposit into secondary bronchi, avoiding systemic absorption typical of alveolar regions. Here, we describe two novel different SLMs prepared with chitosan and alginate for sustained release of fluticasone propionate (…

0301 basic medicineMedicine (miscellaneous)Biocompatible Materials02 engineering and technologyPharmacologymedicine.disease_causeChitosanPulmonary Disease Chronic Obstructivechemistry.chemical_compoundDrug StabilityGlucuronic AcidAdrenal Cortex HormonesMucoadhesive Solid Lipid Nanoparticles (SLMs);Aerodynamic diameter;Chronic obstructive pulmonary disease (COPD)General Materials Sciencechronic obstructive pulmonary disease (COPD)LungChromatography High Pressure LiquidDrug CarriersHexuronic Acidsaerodynamic diameter; chronic obstructive pulmonary disease (COPD); mucoadhesive solid lipid microparticles (SLMs)021001 nanoscience & nanotechnologyLipidsControlled releasemucoadhesive solid lipid microparticles (SLMs)Microspheresmedicine.anatomical_structureDrug deliveryCorticosteroid0210 nano-technologymedicine.drugBiocompatibilityAlginatesCell SurvivalSurface Propertiesmedicine.drug_classBiomedical EngineeringBioengineeringDevelopmentFluticasone propionate03 medical and health sciencesAdministration InhalationmedicineHumansParticle Sizeaerodynamic diameterChitosanLungbusiness.industryEpithelial CellsDrug LiberationOxidative Stress030104 developmental biologychemistryDelayed-Action PreparationsImmunologyMicroscopy Electron ScanningFluticasonebusinessOxidative stress
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct